197 related articles for article (PubMed ID: 18188867)
1. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME
Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
3. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
5. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
6. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
7. Antioxidants block prostate cancer in lady transgenic mice.
Venkateswaran V; Fleshner NE; Sugar LM; Klotz LH
Cancer Res; 2004 Aug; 64(16):5891-6. PubMed ID: 15313934
[TBL] [Abstract][Full Text] [Related]
8. A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model.
Venkateswaran V; Klotz LH; Ramani M; Sugar LM; Jacob LE; Nam RK; Fleshner NE
Cancer Prev Res (Phila); 2009 May; 2(5):473-83. PubMed ID: 19401531
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin - impact on angiogenesis and clinical follow-up.
Heinrich E; Trojan L; Friedrich D; Voss M; Weiss C; Michel MS; Grobholz R
Prostate; 2011 Dec; 71(16):1752-8. PubMed ID: 21480309
[TBL] [Abstract][Full Text] [Related]
10. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
11. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
15. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model.
Uchida K; Masumori N; Takahashi A; Itoh N; Tsukamoto T
Prostate; 2005 Jan; 62(1):40-8. PubMed ID: 15389815
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.
Mucci NR; Akdas G; Manely S; Rubin MA
Hum Pathol; 2000 Apr; 31(4):406-14. PubMed ID: 10821485
[TBL] [Abstract][Full Text] [Related]
17. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
19. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.
Uchida K; Masumori N; Takahashi A; Itoh N; Kato K; Matusik RJ; Tsukamoto T
Prostate; 2006 Apr; 66(5):536-45. PubMed ID: 16372327
[TBL] [Abstract][Full Text] [Related]
20. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]